Findings in Obstructive Sleep Apnea Reported from Chang Gung University (Risk of alzheimer’s disease in obstructive sleep apnea patients with or without treatment: Real-world evidence)

Disease Prevention Daily

2020 FEB 25 (NewsRx) -- By a News Reporter-Staff News Editor at Disease Prevention Daily -- Fresh data on Respiratory Tract Diseases and Conditions - Obstructive Sleep Apnea are presented in a new report. According to news reporting out of Taoyuan, Taiwan, by NewsRx editors, research stated, “To assess the risk of Alzheimer’s disease (AD) in patients with obstructive sleep apnea (OSA) with or without treatment based on real-world evidence. Retrospective cohort study. Patients newly diagnosed with OSA during 1997-2012 were identified using the National Health Insurance Research Database of Taiwan.”

Funders for this research include Chang Gung Medical Foundation, Ministry of Science and Technology, Taiwan.

Our news journalists obtained a quote from the research from Chang Gung University, “Patients without OSA were randomly selected and matched in a 1:4 ratio by age, sex, urbanization level, and income. All patients were followed up until death or the end of 2013. The primary outcome was AD occurrence. This study included 3,978 OSA patients and 15,912 non-OSA patients. OSA was independently and significantly associated with a higher incidence of AD in an adjusted Cox proportional hazard model (adjusted hazard ratio: 2.12; 95% confidence interval [CI], 1.27-3.56). The average period of AD detection from the time of OSA occurrence was 5.44 years (standard deviation: 2.96). Subgroup analyses revealed that the effect of OSA remained significant in patients aged 60 years, male subgroups, patients without CPAP or surgical treatment, and patients without pharmacological therapies. Patients with OSA who received treatment (continuous positive airway pressure or surgery) exhibited a significantly reduced risk of AD compared with those without treatment (incidence rate ratio 0.23, 95% CI, 0.06-0.98). OSA is independently associated with an increased risk of AD. Treatment for OSA reduces the AD risk in OSA patients.”

According to the news editors, the research concluded: “AD irreversibility renders OSA as a potential modifiable target for slowing or preventing the process of AD development.”

For more information on this research see: Risk of alzheimer’s disease in obstructive sleep apnea patients with or without treatment: Real-world evidence. Laryngoscope, 2020;():. Laryngoscope can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA. (Wiley-Blackwell - http://www.wiley.com/; Laryngoscope - http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1531-4995)

Our news journalists report that additional information may be obtained by contacting H.Y. Li, Faculty of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan. Additional authors for this research include M.S. Tsai, C.G. Huang, R.YL. Wang, L.P. Chuang, N.H. Chen, C.H. Liu, Y.H. Yang, C.Y. Liu, C.M. Hsu, W.N. Cheng and L.A Lee.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1002/lary.28558. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the journal Laryngoscope is: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)